A perspective on the trade-offs between safety & efficacy in 1st line RCC
David I. Quinn, MD,the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The trade-offs between safety & efficacy in 1st line RCC treatment
Primo N. Lara, Jr., MD, explains the trade-offs between safety and efficacy when considering 1st line renal cell carcinoma (RCC) treatment options
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The convenience of oral TKIs impacts RCC treatment
David I. Quinn, MD, discusses whether the convenience factor of oral TKIs enters into the decision-making process when treating advanced renal cell carcinoma (RCC) patients
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The treatment path following I-O failure
Primo N. Lara, Jr., MD, explains how a newly diagnosed advanced renal cell carcinoma (RCC) patient should be treated in the 2nd line following I-O failure at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Which mRCC patients should receive a TKI
Primo N. Lara, Jr., MD, explains how he decides which metastatic renal cell carcinoma (mRCC) patients should receive a TKI as 1st line therapy
Author: obr
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
How checkpoint inhibitors fit into RCC treatment algorithms
Primo N. Lara, Jr., MD, explains how how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients at ASCO 2018.
Author: obr
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Exciting RCC data coming out of ASCO 2018
David I. Quinn, MD, shares his thoughts on the most interesting renal cell carcinoma (RCC) data being presented at the 2018 ASCO Annual Meeting.
Author: obr
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
The shortcomings of the RECIST study in HCC
Ghassan Abou-Alfa, MD, MBA, explains the shortcomings of the RECIST study in measuring efficacy in hepatocellular carcinoma (HCC) patients at ASCO 2018.
Author: obr
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
The latest in systemic therapy for advanced HCC
Ghassan Abou-Alfa, MD, MBA, talks about the latest in systemic therapy for advanced hepatocellular carcinoma (HCC) at the 2018 ASCO Annual Meeting
Author: obr
Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts
How checkpoint inhibitors fit into RCC treatment algorithms
Jeanny B. Aragon-Ching, MD, FACP, discusses how checkpoint inhibitors figure into the treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients at ASCO 2018.
Author: obr
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Trade-offs between safety & efficacy when discussing 1st line RCC
Robert A. Figlin, MD, explains the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
Author: obr
Added: 07/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Perspective on I-O failures
Robert A. Figlin, MD, talks about the best actions to take if newly diagnosed advanced renal cell carcinoma (RCC) patients receive nivolumab & ipilimumab but continues to progress at ASCO 2018.
Author: obr
Added: 07/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Sensitivity for BCLC for Stage A was 93% & #124; Detect Hepatocellular Carcinoma Lesions in Future
Dr. John Kisiel, MD, Mayo Clinic, talks Sensitivity for BCLC for Stage A was 93%| Detect Hepatocellular Carcinoma Lesions in Future for DDW 2018.
Author: Cancer-News
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Develop Novel, Non-Invasive Biomarkers | Clinical Validation Study in Hepatocellular Carcinoma
Dr. John Kisiel, MD, Mayo Clinic, talks about Develop Novel, Non-Invasive Biomarkers | Clinical Validation Study in Hepatocellular Carcinoma for DDW 2018.
Author: Cancer-News
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Issue Summary: July 2018
David A. Bluemke, MD, PhD, Editor of Radiology discusses four research articles from the July 2018 issue of Radiology. ARTICLES DISCUSSED Summary of Outcome of Architectural Distortion Detected Only at Breast Tomosynthesis versus 2D Mammography Radiology 2018;288(1):38-46. Summary of Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study. Radiology 2018;288(1):47-54. Summary of Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Resu...
Source: Radiology Podcasts - July 5, 2018 Category: Radiology Authors: The Radiological Society of North America Tags: Podcasts Source Type: podcasts
